Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343755 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT04343755 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 52 participants.
The verdict
NCT04343755, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
* This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. * Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. * Interim analysis will be permitted as described in the statistical section 8. * The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.
Interventions
- BIOLOGICAL Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343755
The ClinicalTrials.gov registry entry for NCT04343755 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04343755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04343755 about?
NCT04343755 is a clinical study titled "Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection". * This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. * Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. * Interim analysis will be permitte...
What is the current status of trial NCT04343755?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-04-09. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT04343755?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04343755?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.